Pamidronate disodium[ (Aredia) ] Drug Information

Contains Pamidronate disodium drug information and provides Pamidronate disodium drug indication, contraindication, special concerns, side effects, overdose management and dosage
Search Drugs by Generic or Trade Name:
Browse Drugs by Generic Name:
[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z ]

In conjunction with hydration to treat moderate to severe hypercalcemia associated with malignancy (with or without bone metastases). Moderate to severe Paget's disease. In conjunction with antimyeloma chemotherapy to treat osteolytic bone lesions of multiple myeloma or osteolytic bone metastases of breast cancer. Investigational: Postmenopausal osteoporosis; hyperparathyroidism; prophylaxis of glucocorticoid-induced osteoporosis; reduce bone pain in clients with prostatic carcinoma; treat immobilization-induced hypercalcemia.
Back to Top
Hypersensitivity to biphosphonates.
Back to Top
Special Concerns:
Use with caution during lactation. Safety and effectiveness have not been determined in children. Pamidronate has not been tested in clients who have creatinine levels greater than 5 mg/dL.
Back to Top
Side Effects:
Metabolic/Electrolytes: Hypocalcemia, hypokalemia, hypomagnesemia, hypophosphatemia, hypomagnesemia. Body as a whole: Slight increase in body temperature, fluid overload, generalized pain, back pain, fatigue, fever, moniliasis. GI: N&V, constipation, abdominal pain, anorexia, GI hemorrhage ulcerative stomatitis. CNS: Somnolence, insomnia, dizziness, headache, paresthesia, abnormal vision, slight possibility of seizures. CV: Hypertension, atrial fibrillation, syncope, tachycardia. Respiratory: Rales, rhinitis, upper respiratory tract infection. GU: UTI. Musculoskeletal: Bone pain. At site of administration: Redness, swelling or induration, pain on palpation. Miscellaneous: Anemia, hypothyroidism, sweating.
Back to Top
Overdose Management:
No Available information
Back to Top
Drug Interactions:
No Available information
Back to Top
•IV Infusion Moderate hypercalcemia (corrected serum calcium of about 12-13.5 mg/dL) of malignancy.

Initial therapy: 60-90 mg. The 60-mg dose is given as an initial single dose over at least 4 hr; the 90-mg dose must be given as an initial single dose over 24 hr.

Severe hypercalcemia (corrected serum calcium greater than 13.5 mg/dL) of malignancy.

Initial therapy: 90 mg as a single initial dose given over 24 hr. If retreatment is necessary, use the same dose as for initial therapy; at least 7 days should elapse before retreatment.

Moderate to severe Paget's disease.

30 mg/day given as a 4-hr infusion on 3 consecutive days (total dose: 90 mg). If retreatment is necessary, the same dosage schedule is used.

Osteolytic bone lesions of multiple myeloma.

90 mg given as a 4-hr infusion every month. Those with marked Bence-Jones proteinuria and dehydration should receive adequate hydration before infusion of pamidronate.

Osteolytic bone metastases.

90 mg given as a 2-hr infusion q 3 to 4 weeks.
Back to Top